Pathstone Holdings
JAZZ icon

Pathstone Holdings’s Jazz Pharmaceuticals JAZZ Stock Holding History

Pathstone Holdings’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.65M Buy
15,152
+1,205
+9% +$264K 0.01% 795
2026
Q1 		$2.64M Buy
13,947
+2,764
+25% +$483K 0.01% 890
2025
Q4 		$1.9M Buy
11,183
+728
+7% +$112K 0.01% 1046
2025
Q3 		$1.38M Buy
10,455
+1,305
+14% +$157K 0.01% 1243
2025
Q2 		$971K Buy
9,150
+4,733
+107% +$514K ﹤0.01% 1410
2025
Q1 		$548K Sell
4,417
-47
-1% -$6.13K ﹤0.01% 1679
2024
Q4 		$550K Buy
4,464
+156
+4% +$18.4K ﹤0.01% 1681
2024
Q3 		$480K Buy
4,308
+67
+2% +$7.34K ﹤0.01% 1746
2024
Q2 		$453K Buy
4,241
+850
+25% +$93.5K ﹤0.01% 1749
2024
Q1 		$408K Buy
3,391
+359
+12% +$44K ﹤0.01% 1776
2023
Q4 		$373K Buy
+3,032
New +$378K ﹤0.01% 1687

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Pathstone Holdings's JAZZ Position: Q2 2026 in Review

Pathstone Holdings increased its Jazz Pharmaceuticals (JAZZ) stake by 8.6% in Q2 2026, buying an estimated $264K and bringing the position to 15,152 shares worth $3.65M. The position accounts for 0.01% of the portfolio, ranked #795.

Pathstone Holdings first reported a position in JAZZ in Q4 2023 and has held it in 11 quarters since. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Pathstone Holdings held 15,152 shares of Jazz Pharmaceuticals worth $3.65M as of Q2 2026.
  • Pathstone Holdings bought 1,205 Jazz Pharmaceuticals shares in Q2 2026, an estimated $264K.
  • Jazz Pharmaceuticals made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #795 holding.
  • Pathstone Holdings first reported a position in Jazz Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.